(DRRX)

Bausch Health will acquire DURECT for $63 million upfront, gaining rights to larsucosterol, a promising drug candidate for treating alcoholic hepatitis, with potential additional milestone payments of up to $350 million.

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.

Welcome to another installment of our monthly Rare Stock Picks article, where we highlight investment picks you may have missed. Explore more details here.